Literature DB >> 8384821

2-Acetylpyridine 5-[(dimethylamino)thiocarbonyl]-thiocarbonohydrazone (1110U81) potently inhibits human cytomegalovirus replication and potentiates the antiviral effects of ganciclovir.

F M Hamzeh1, T Spector, P S Lietman.   

Abstract

We studied the effects of 2-acetylpyridine 5-[(dimethylamino)thiocarbonyl]-thiocarbonohydrazone (1110U81 or A1110U), a potent inhibitor of the ribonucleotide reductases encoded by herpes simplex virus types 1 and 2 and by varicella-zoster virus, against human cytomegalovirus (HCMV) replication in infected MRC-5 cells. We show that 1110U81 is a potent inhibitor of HCMV DNA replication (50% inhibitory concentration [IC50], 3.6 microM; IC90, 5.6 microM) and also potentiates the effects of ganciclovir (GCV) against HCMV. The IC90 of GCV is reduced from 65 microM when GCV alone is given to 2.8 microM when GCV is combined with 1110U81 at a molar ratio of 1:1.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8384821      PMCID： PMC187714          DOI： 10.1128/AAC.37.3.602

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  22 in total

Review 1.  Reduction of ribonucleotides.

Authors:  L Thelander; P Reichard
Journal:  Annu Rev Biochem       Date:  1979       Impact factor: 23.643

2.  Ribonucleotide reductase of herpes simplex virus type 2 resembles that of herpes simplex virus type 1.

Authors:  D R Averett; P A Furman; T Spector
Journal:  J Virol       Date:  1984-12       Impact factor: 5.103

3.  Characterization of ribonucleotide reductase induction in BHK-21/C13 Syrian hamster cell line upon infection by herpes simplex virus (HSV).

Authors:  Y Langelier; G Buttin
Journal:  J Gen Virol       Date:  1981-11       Impact factor: 3.891

4.  Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors.

Authors:  T C Chou; P Talalay
Journal:  Adv Enzyme Regul       Date:  1984

5.  Ribonucleotide reductase induced by herpes simplex virus has a virus-specified constituent.

Authors:  B M Dutia
Journal:  J Gen Virol       Date:  1983-03       Impact factor: 3.891

6.  Cloning of the human cytomegalovirus genome as endonuclease XbaI fragments.

Authors:  D R Thomsen; M F Stinski
Journal:  Gene       Date:  1981-12       Impact factor: 3.688

Review 7.  Models of the regulation of ribonucleotide reductase and their evaluation in intact mammalian cells.

Authors:  D Hunting; J F Henderson
Journal:  CRC Crit Rev Biochem       Date:  1982

8.  Ribonucleotide reductase from herpes simplex virus (types 1 and 2) infected and uninfected KB cells: properties of the partially purified enzymes.

Authors:  M Ponce de Leon; R J Eisenberg; G H Cohen
Journal:  J Gen Virol       Date:  1977-07       Impact factor: 3.891

9.  Inactivators of herpes simplex virus ribonucleotide reductase: hematological profiles and in vivo potentiation of the antiviral activity of acyclovir.

Authors:  T Spector; D C Lobe; M N Ellis; T A Blumenkopf; G M Szczech
Journal:  Antimicrob Agents Chemother       Date:  1992-05       Impact factor: 5.191

10.  Ribonucleotide reductase induced by herpes simplex type 1 virus. Characterization of a distinct enzyme.

Authors:  D R Averett; C Lubbers; G B Elion; T Spector
Journal:  J Biol Chem       Date:  1983-08-25       Impact factor: 5.157
View more
  3 in total

1.  Anticytomegaloviral activity of methotrexate associated with preferential accumulation of drug by cytomegalovirus-infected cells.

Authors:  M Wachsman; F M Hamzeh; H Saito; P S Lietman
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

2.  Ribonucleotide reductase inhibitors hydroxyurea, didox, and trimidox inhibit human cytomegalovirus replication in vitro and synergize with ganciclovir.

Authors:  Sukhada Bhave; Howard Elford; Michael A McVoy
Journal:  Antiviral Res       Date:  2013-08-06       Impact factor: 5.970

Review 3.  Ganciclovir. An update of its therapeutic use in cytomegalovirus infection.

Authors:  A Markham; D Faulds
Journal:  Drugs       Date:  1994-09       Impact factor: 9.546
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.